Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Dr. Crompton on Challenges With Liquid Biopsies in Pediatric Sarcoma

October 22nd 2018

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the challenges associated with implementing liquid biopsies in pediatric sarcoma.

Identification of Combinations For Pediatric Rhabdomyosarcomas

October 22nd 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.

Dr. Tasian on Frontline Therapy for Pediatric Patients With Ph-Like ALL

October 18th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), discusses frontline therapy for pediatric patients with Ph-like acute lymphoblastic leukemia (ALL).

Next Steps With the St. Jude Lifetime Cohort Study

October 17th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the next steps of the St. Jude Lifetime Cohort Study.

Dr. Upadhyaya on Outcomes for Children on the SJYC07 Trial

October 12th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

Dr. Tasian on Genetic Testing in Pediatric ALL

October 10th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses genetic testing in pediatric acute lymphoblastic leukemia.

Dr. Link on the Current State of Treatment For Pediatric Cancer

October 8th 2018

Michael Link, MD, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology discusses the current paradigm for treatment in pediatric cancer.

Dr. Patterson on Off-Target Effects With TKIs in Pediatric CML

October 5th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the off-target effects with tyrosine kinase inhibitors (TKIs) in pediatric patients with chronic myeloid leukemia (CML).

Dr. Upadhyaya on the Design of the SJYC07 Trial in Pediatric Patients With Ependymoma

October 4th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the design of the 10-year-long SJYC07 trial.

Link Lends Insight on Progress, Challenges in Pediatric Cancer

October 3rd 2018

Michael Link, MD, a 2018 Giant of Cancer Care® in Pediatric Oncology, discusses the exciting progress being made for various pediatric tumors.

Dr. Tasian on Challenges in Treating Pediatric Patients With Ph-Like ALL

September 19th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

Recognizing Predisposition Syndromes Can Impact Pediatric MDS and AML Treatment

September 14th 2018

Early identification of inherited predisposition to forms of myelodysplastic syndrome and acute myeloid leukemia in pediatric patients can assist in treatment decisions and selection for familial stem cell transplant.

Future of AYA ALL Research Should Include Eliminating MRD, Treating High-Risk Patients

September 13th 2018

Following survival improvements in the field of adolescents and young adults with acute lymphoblastic leukemia, researchers must turn their focus to lowering toxicity, and delivering treatment to high-risk subgroups, among others.

Expert Emphasizes Importance of Collaboration for Rare Pediatric Cancers

September 10th 2018

Matthew Ladra, MD, MPH, discusses the treatment of patients with esthesioneuroblastoma, emphasizing the need for collaboration in this rare malignancy.

Study Evaluates Risk of Breast Cancer for Childhood Survivors of Cancer

September 7th 2018

Zhaoming Wang, PhD, discusses the first assessment of the joint effects of rare and common genetic variations in survivors of childhood cancers.

Dr. Bosse on Immunotherapy in Pediatric Cancers

September 6th 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the use of immunotherapy in the treatment of pediatric patients with cancer.

FDA Grants Pembrolizumab Priority Review for Merkel Cell Carcinoma

September 4th 2018

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for the treatment of pediatric and adult patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Genomic Era Reaches Pediatric Oncology

September 4th 2018

Technological advancements in molecular tumor profiling are starting to make a difference in pediatric oncology, where the search for new therapies is challenging and frustrating.

A Legacy of Hope for Young Leukemia Patients

September 3rd 2018

Joseph V. Simone, MD, is best known for leading the research efforts that resulted in the first curative combination treatment for certain pediatric patients with acute lymphoid leukemia. Under his leadership, the St. Jude Children’s Research Hospital in Memphis, Tennessee, was designated the first and only National Cancer Institute cancer center dedicated to children. He was honored in the Pediatric Oncology category with a 2017 Giants of Cancer Care® award.

FDA Accepts Application for Dasatinib for Pediatric Ph+ ALL

August 30th 2018

The FDA has accepted a supplemental biologics license application for dasatinib for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.